
CytoSorbents (CTSO) Stock Forecast & Price Target
CytoSorbents (CTSO) Analyst Ratings
Bulls say
CytoSorbents Corp has demonstrated a solid financial trajectory, with fourth quarter gross margin expected to reach 73% to 75%, contributing to a full-year gross margin improvement to approximately 72%, indicative of operational efficiency. The company achieved $9.5 million in revenue for the quarter, reflecting a 10% year-over-year growth, driven by enhanced distributor-driven sales and improving geographic market execution. Additionally, recent clinical publications and the advancement of DrugSorb-ATR toward FDA submission bolster the firm's strategic position and potential for future growth across various critical care applications.
Bears say
CytoSorbents Corp reported fourth-quarter revenue of approximately $9.2 million, remaining flat year-over-year, while the full-year revenue reached about $37 million, showing only 4% growth compared to the previous year. Management has noted patient imbalances in the initial U.S. market, which could signal underlying challenges in demand and market acceptance of their products. The company's current valuation appears to be distressed, reflecting market concerns that are largely independent of the company's fundamental performance metrics.
This aggregate rating is based on analysts' research of CytoSorbents and is not a guaranteed prediction by Public.com or investment advice.
CytoSorbents (CTSO) Analyst Forecast & Price Prediction
Start investing in CytoSorbents (CTSO)
Order type
Buy in
Order amount
Est. shares
0 shares